
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New ...
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward …